The document provides financial highlights for NNIT's first nine months of 2017, including a 2.1% increase in revenue to DKK 2,080m and a 3.3% increase in order backlog to DKK 2,750m. Revenue growth was negatively impacted by a one-time DKK 33m revenue reversal from an arbitration settlement. Operating profit declined 16.6% to DKK 163.6m due to the revenue reversal and lower margin project work for Novo Nordisk. Segment revenue increased for life sciences and enterprise customers but declined for public sector and Novo Nordisk customers.
NNIT reported financial results for the first six months of 2017, with revenue growing 6.3% to DKK 1,404 million. Operating profit increased 5.3% to DKK 133 million and net profit grew 11.7% to DKK 103 million. Order backlog increased 5.4% to DKK 2,659 million. Revenue growth was driven by new customers in life sciences and enterprise segments, while margins declined slightly due to lower activity from Novo Nordisk and onboarding costs for new customers. NNIT affirmed its outlook for 2017.
The document provides highlights and financial information for NNIT for the first six months of 2018. Key points include:
- Revenue for Q2 2018 increased 8.3% to DKK 753 million and increased 2.9% to DKK 1,451 million for the first six months of 2018.
- Operating profit for Q2 2018 was DKK 75 million, up 22%, and was DKK 135 million for the first six months, down 0.6%.
- Order backlog for 2018 increased 0.4% to DKK 2,682 million compared to the same period in 2017.
NNIT presented its full-year report for 2016 in a presentation spanning highlights for the year, sales and backlog figures, financial performance, and an outlook for 2017. Key points included revenue growth of 6.3% to DKK 2,765 million and operating profit growth of 8.8% to DKK 293 million. The order backlog increased 3.6% to DKK 2,093 million. Segment revenue growth was driven by life sciences customers outside Novo Nordisk and strong growth in the enterprise and finance segments.
NNIT reported financial results for the first quarter of 2018. Revenue declined 2.3% to DKK 699 million due to a 20% decline in revenue from Novo Nordisk. Operating profit was DKK 61 million with an operating margin of 8.7%. Order backlog for 2018 increased 2.8% to DKK 2,487 million. Major new contract wins in the quarter included an infrastructure outsourcing contract and an SAP implementation project. The outlook for 2018 was maintained.
Bruker reported Q2 2017 financial results with revenue increasing 11.6% year-over-year to $414.9 million. Organic revenue growth was 7.6% while acquisitions contributed 5.8% growth. The operating margin expanded 170 basis points to 12.5% of revenues due to revenue growth and 2016 restructuring benefits. Non-GAAP EPS grew 15% to $0.23 per share despite a higher effective tax rate compared to the prior year period. For the full year 2017, Bruker expects revenue to increase 4.5-6.0% and for the non-GAAP operating margin to expand 40-70 basis points.
NNIT reported financial results for Q4 2017 and full year 2017. For Q4, revenue increased 5.6% to DKK 812 million driven by growth in life sciences and enterprise customers. Operating profit grew 16.9% to DKK 113 million and net profit increased 19.6% to DKK 86 million. For the full year, revenue grew 4.6% while operating profit declined 5.5% and net profit grew 0.4% due to the impact of settlements earlier in 2017. NNIT also provided commentary on business segment performance and outlook.
Bruker Corporation reported financial results for Q4 2017 and FY 2017. In Q4, revenues increased 12.8% year-over-year to $530.5 million, driven by 4.0% organic growth, a 5.2% benefit from currency fluctuations, and 3.6% from acquisitions. Non-GAAP operating profit grew 20.4% and non-GAAP earnings per share increased 11% compared to Q4 2016. For FY 2017, revenues grew 9.6% to $1.766 billion with 3.6% organic growth, a 1.2% currency benefit, and 4.8% from acquisitions, while non-GAAP operating margins expanded.
NNIT reported financial results for the first six months of 2017, with revenue growing 6.3% to DKK 1,404 million. Operating profit increased 5.3% to DKK 133 million and net profit grew 11.7% to DKK 103 million. Order backlog increased 5.4% to DKK 2,659 million. Revenue growth was driven by new customers in life sciences and enterprise segments, while margins declined slightly due to lower activity from Novo Nordisk and onboarding costs for new customers. NNIT affirmed its outlook for 2017.
The document provides highlights and financial information for NNIT for the first six months of 2018. Key points include:
- Revenue for Q2 2018 increased 8.3% to DKK 753 million and increased 2.9% to DKK 1,451 million for the first six months of 2018.
- Operating profit for Q2 2018 was DKK 75 million, up 22%, and was DKK 135 million for the first six months, down 0.6%.
- Order backlog for 2018 increased 0.4% to DKK 2,682 million compared to the same period in 2017.
NNIT presented its full-year report for 2016 in a presentation spanning highlights for the year, sales and backlog figures, financial performance, and an outlook for 2017. Key points included revenue growth of 6.3% to DKK 2,765 million and operating profit growth of 8.8% to DKK 293 million. The order backlog increased 3.6% to DKK 2,093 million. Segment revenue growth was driven by life sciences customers outside Novo Nordisk and strong growth in the enterprise and finance segments.
NNIT reported financial results for the first quarter of 2018. Revenue declined 2.3% to DKK 699 million due to a 20% decline in revenue from Novo Nordisk. Operating profit was DKK 61 million with an operating margin of 8.7%. Order backlog for 2018 increased 2.8% to DKK 2,487 million. Major new contract wins in the quarter included an infrastructure outsourcing contract and an SAP implementation project. The outlook for 2018 was maintained.
Bruker reported Q2 2017 financial results with revenue increasing 11.6% year-over-year to $414.9 million. Organic revenue growth was 7.6% while acquisitions contributed 5.8% growth. The operating margin expanded 170 basis points to 12.5% of revenues due to revenue growth and 2016 restructuring benefits. Non-GAAP EPS grew 15% to $0.23 per share despite a higher effective tax rate compared to the prior year period. For the full year 2017, Bruker expects revenue to increase 4.5-6.0% and for the non-GAAP operating margin to expand 40-70 basis points.
NNIT reported financial results for Q4 2017 and full year 2017. For Q4, revenue increased 5.6% to DKK 812 million driven by growth in life sciences and enterprise customers. Operating profit grew 16.9% to DKK 113 million and net profit increased 19.6% to DKK 86 million. For the full year, revenue grew 4.6% while operating profit declined 5.5% and net profit grew 0.4% due to the impact of settlements earlier in 2017. NNIT also provided commentary on business segment performance and outlook.
Bruker Corporation reported financial results for Q4 2017 and FY 2017. In Q4, revenues increased 12.8% year-over-year to $530.5 million, driven by 4.0% organic growth, a 5.2% benefit from currency fluctuations, and 3.6% from acquisitions. Non-GAAP operating profit grew 20.4% and non-GAAP earnings per share increased 11% compared to Q4 2016. For FY 2017, revenues grew 9.6% to $1.766 billion with 3.6% organic growth, a 1.2% currency benefit, and 4.8% from acquisitions, while non-GAAP operating margins expanded.
Lkq corporations fourth quarter and full year 2016 earnings call presentationcorporationlkq
Fourth Quarter & Full Year 2016 Earnings Call
- For Q4 2016, revenue increased 23.0% to $2.15 billion due to a 22.2% increase from acquisitions and 3.8% organic growth. Income from continuing operations was $96.3 million.
- For full year 2016, revenue increased 19.3% to $8.58 billion due to an 18.0% increase from acquisitions and 3.7% organic growth. Income from continuing operations was $456.1 million.
- Key acquisitions in 2016 included Rhiag-Inter Auto Parts Italia S.p.A. and the aftermarket glass business of PPG Industries, which
- LKQ reported revenue of $9.7B for Q4 2017, up 14.9% year-over-year, and $37B for full year 2017, up 13.4% year-over-year. Organic growth was a major contributor.
- Net income for Q4 2017 was $126M, up 31% year-over-year, and $540M for full year 2017, up 18% year-over-year.
- Segment EBITDA margins were 10.3% for Q4 2017 and 11.5% for full year 2017.
This document provides an overview of Nelnet's business segments and financial performance. The key points are:
- Nelnet has four business segments: NDS (loan origination/servicing software), NBS (education payment processing software), AGM (student loan asset management), and ALLO (fiber network provider).
- Over the past decade, Nelnet has diversified its business and grown revenues across all segments. Adjusted net income has increased from $41 million in 2007 to over $200 million in recent years.
- Nelnet services over $195 billion in student loans for nearly 10 million borrowers. Its student loan portfolio is expected to generate $2.07 billion in future cash flows.
- WestRock reported Q2 FY17 results with adjusted EPS of $0.54 and adjusted free cash flow of $109 million.
- Segment sales were $3.656 billion. Productivity initiatives contributed $103 million in cost savings.
- Corrugated packaging sales were $2.065 billion. North America EBITDA margin was 15.9%.
- Consumer packaging sales were $1.555 billion. Adjusted segment EBITDA margin increased 100 bps to 15.1%.
- Land and development segment income was $18 million, excluding a $43 million impairment charge. The monetization program is on track to generate $150-175 million in after-tax cash flow for
Third Quarter 2017 Earnings Call Presentationcorporationlkq
- LKQ reported revenue of $2.5B for Q3 2017, up 11.7% from Q3 2016, and revenue of $7.3B for the first nine months of 2017, up 13% from the same period in 2016. Organic revenue growth was 3.2% for Q3 and 3.8% for the first nine months.
- Income from continuing operations was $122M for Q3 2017 compared to $110M for Q3 2016. For the first nine months it was $414M in 2017 compared to $360M in 2016.
- Inventory levels are sufficient to support growth targets, with aftermarket purchases up 9.3% in Q3 2017 and 12
- Bruker Corporation reported financial results for Q1 2018 with total revenues increasing 12.2% year-over-year to $431.7 million.
- Organic revenue growth was 4.0% including 3.8% growth in the Scientific Instruments segment. Foreign exchange rates contributed 7.7% to total revenue growth.
- Non-GAAP earnings per share increased 26% to $0.24 compared to $0.19 in Q1 2017, driven by revenue growth and a lower tax rate partially offset by foreign exchange headwinds.
Lkq second quarter 2017 earnings call presentationcorporationlkq
- LKQ reported revenue of $2.458 billion for Q2 2017, up 6.7% from Q2 2016, with organic growth of parts and services revenue of 3.8%. Net income was $150.9 million.
- For YTD 2017, revenue was $4.801 billion, up 13.6% from YTD 2016, with organic growth of parts and services revenue of 4.1%. Net income was $291.7 million.
- Segment EBITDA margins were 12.4% for Q2 2017 and YTD 2017, down from 13.0% for Q2 2016 but flat compared to 12.7% for YTD 2016.
- The company reported revenue of $2.34 billion for Q1 2017, up 21.9% from Q1 2016, driven by organic growth, acquisitions, and higher scrap steel prices.
- Income from continuing operations was $140.8 million for Q1 2017 compared to $112.2 million for Q1 2016.
- Segment EBITDA margin was 12.4% for Q1 2017 compared to 12.3% for Q1 2016, as revenue growth offset increased operating expenses from acquisitions.
Barry Callebaut Group - Half-Year Results Fiscal Year 2017/18 - Media/Analyst...Barry Callebaut
Antoine de Saint-Affrique, CEO of the Barry Callebaut Group, said: “We had a very strong performance in the first six months of the current fiscal year, which was supported by all product groups and regions, as well as our key growth drivers. This resulted in the continued improvement of our profitability, driven by a favorable mix, operational leverage and a more supportive market.”
Bruker reported financial results for Q3 2018 and year-to-date Q3 2018. Q3 revenue increased 7.1% year-over-year to $466.6 million driven by 7% organic growth. Non-GAAP operating income grew 27% and margin expanded 280 basis points. Year-to-date revenue increased 8.6% to $1,342 million with organic growth of 4.7%. Non-GAAP EPS grew 28% in Q3 and 23% year-to-date as revenue growth and margin expansion drove higher profits. Bruker aims to continue revenue growth acceleration through initiatives like acquisitions and new facilities.
Oshkosh Corporation reported its financial results for the second quarter of fiscal year 2017. Net sales increased 6.2% to $1.618 billion compared to the same period last year, and adjusted earnings per share were $0.76, equal to the prior year. The defense segment performed well due to the JLTV program ramp up and international sales. The access equipment and commercial segments faced challenges with lower sales volumes impacting operating income. For fiscal year 2017, the company increased its adjusted EPS outlook to a range of $3.20 to $3.50.
- Cardinal Health reported Q4 FY2017 revenue of $32.966 billion, a 5% increase over the prior year. Operating earnings were $439 million, a 29% decrease.
- Revenue in the Pharmaceutical segment increased 5% to $29.552 billion driven by distribution customer and specialty solutions growth. Segment profit decreased 7% to $505 million due to generic pricing and IT investment.
- The Medical segment saw 6% revenue growth to $3.416 billion from new and existing customers. Segment profit rose 13% to $138 million from post-acute solutions and distribution growth.
The document recommends buying shares of Busan City Gas (BCG) based on the following points:
1. BCG has a monopoly on natural gas distribution in Busan, Korea, generating predictable cash flows. However, its stock price fell due to a one-time earnings decline and now offers upside.
2. BCG's intrinsic value exceeds its stock price, which fails to account for undervalued real estate assets.
3. The majority owner of BCG may fully acquire the company, unlocking its true value for shareholders.
This annual report provides information on China Mobile Limited for the 2008 fiscal year. It includes the chairman's statement which discusses the company maintaining growth in new customers, business, and voice usage. Financial highlights show increases in key financial figures such as revenue and profit for the year from 2005 to 2008. The business review discusses the company expanding its subscriber base and stimulating voice usage. The financial review analyzes expenses and their increases from the prior fiscal year.
A survey found that:
- 79% of respondents saw their sales reduce in 2020, with over 40% seeing a reduction of over 50% compared to 2019.
- 62% of respondents reduced their purchases due to Covid-19 across many locations and industries.
- 70% of respondents experienced delays with their orders.
- 70% of respondents were willing to accept delays of over 10 days from suppliers because of Covid-19.
- 86% of respondents were optimistic that 2021 will be better than 2020.
This document provides a summary of Ingersoll Rand's first quarter 2017 results. Some key points:
- Revenue increased 4% year-over-year on an organic basis to $3 billion. Adjusted EPS increased 14% to $0.57.
- Commercial and residential HVAC businesses saw strong revenue and bookings growth in the high-single digits. Industrial business bookings were up 9%.
- Adjusted operating margins improved in both the climate and industrial segments.
- Guidance for full-year 2017 revenue growth remains at 2-3% organic and adjusted EPS is increased to a range of $4.35 to $4.50.
- The document provides an earnings conference call summary for Q4 and Fiscal Year 2017.
- Key highlights include net sales growth of 12% in Q4 and 9% for FY 2017, and operating profit before special items growth of 2% in Q4 and 9% for FY 2017.
- Class A EPS before special items grew 51% in Q4 to $0.98 per share and grew 21% for FY 2017 to $2.95 per share.
- The document outlines Greif's December 2017 investor meetings, including forward-looking statements, regulation G definitions, and Greif's business segments.
- Greif has four business segments: Rigid Industrial Packaging & Services (RIPS), Paper Packaging & Services (PPS), Flexible Products & Services (FPS), and Land Management.
- Greif has a global footprint with operations in over 40 countries and focuses on customer service excellence through its Greif Business System (GBS).
In the first six months of 2017, NNIT saw revenue growth of 6.3% to DKK 1,404 million. Operating profit increased 6.3% to DKK 133 million and net profit grew 11.7% to DKK 103.4 million. Order backlog increased 5.4% to DKK 2,659 million. Revenue growth was driven by life sciences customers outside Novo Nordisk and new customers in the enterprise segment. Operating profit margin declined slightly due to lower margin projects from Novo Nordisk and onboarding new customers. The outlook for 2017 remains unchanged with organic revenue growth of 3-5% and an operating profit margin above 9%.
Bruker Corporation reported financial results for Q3 2017 and year-to-date Q3 2017. Revenue increased 10.6% in Q3 2017 and 8.3% year-to-date, driven by organic growth and acquisitions. Operating profit grew 10% in Q3 2017 and 13% year-to-date. However, earnings per share declined in both periods compared to the prior year due to a higher effective tax rate in 2017. The company continues to focus on revenue growth, margin expansion, and portfolio transformation through new product development and acquisitions.
First three months of 2017 Roadshow presentationNNiTInvestor
NNIT reported financial results for the first quarter of 2017. Revenue increased 4.3% to DKK 715 million, while operating profit rose 8% to DKK 73 million. Order backlog grew 7.9% organically to DKK 2,385 million. NNIT also announced the renewal of its global infrastructure agreement with Novo Nordisk and the acquisition of Dynamics AX consultancy SCALES.
Lkq corporations fourth quarter and full year 2016 earnings call presentationcorporationlkq
Fourth Quarter & Full Year 2016 Earnings Call
- For Q4 2016, revenue increased 23.0% to $2.15 billion due to a 22.2% increase from acquisitions and 3.8% organic growth. Income from continuing operations was $96.3 million.
- For full year 2016, revenue increased 19.3% to $8.58 billion due to an 18.0% increase from acquisitions and 3.7% organic growth. Income from continuing operations was $456.1 million.
- Key acquisitions in 2016 included Rhiag-Inter Auto Parts Italia S.p.A. and the aftermarket glass business of PPG Industries, which
- LKQ reported revenue of $9.7B for Q4 2017, up 14.9% year-over-year, and $37B for full year 2017, up 13.4% year-over-year. Organic growth was a major contributor.
- Net income for Q4 2017 was $126M, up 31% year-over-year, and $540M for full year 2017, up 18% year-over-year.
- Segment EBITDA margins were 10.3% for Q4 2017 and 11.5% for full year 2017.
This document provides an overview of Nelnet's business segments and financial performance. The key points are:
- Nelnet has four business segments: NDS (loan origination/servicing software), NBS (education payment processing software), AGM (student loan asset management), and ALLO (fiber network provider).
- Over the past decade, Nelnet has diversified its business and grown revenues across all segments. Adjusted net income has increased from $41 million in 2007 to over $200 million in recent years.
- Nelnet services over $195 billion in student loans for nearly 10 million borrowers. Its student loan portfolio is expected to generate $2.07 billion in future cash flows.
- WestRock reported Q2 FY17 results with adjusted EPS of $0.54 and adjusted free cash flow of $109 million.
- Segment sales were $3.656 billion. Productivity initiatives contributed $103 million in cost savings.
- Corrugated packaging sales were $2.065 billion. North America EBITDA margin was 15.9%.
- Consumer packaging sales were $1.555 billion. Adjusted segment EBITDA margin increased 100 bps to 15.1%.
- Land and development segment income was $18 million, excluding a $43 million impairment charge. The monetization program is on track to generate $150-175 million in after-tax cash flow for
Third Quarter 2017 Earnings Call Presentationcorporationlkq
- LKQ reported revenue of $2.5B for Q3 2017, up 11.7% from Q3 2016, and revenue of $7.3B for the first nine months of 2017, up 13% from the same period in 2016. Organic revenue growth was 3.2% for Q3 and 3.8% for the first nine months.
- Income from continuing operations was $122M for Q3 2017 compared to $110M for Q3 2016. For the first nine months it was $414M in 2017 compared to $360M in 2016.
- Inventory levels are sufficient to support growth targets, with aftermarket purchases up 9.3% in Q3 2017 and 12
- Bruker Corporation reported financial results for Q1 2018 with total revenues increasing 12.2% year-over-year to $431.7 million.
- Organic revenue growth was 4.0% including 3.8% growth in the Scientific Instruments segment. Foreign exchange rates contributed 7.7% to total revenue growth.
- Non-GAAP earnings per share increased 26% to $0.24 compared to $0.19 in Q1 2017, driven by revenue growth and a lower tax rate partially offset by foreign exchange headwinds.
Lkq second quarter 2017 earnings call presentationcorporationlkq
- LKQ reported revenue of $2.458 billion for Q2 2017, up 6.7% from Q2 2016, with organic growth of parts and services revenue of 3.8%. Net income was $150.9 million.
- For YTD 2017, revenue was $4.801 billion, up 13.6% from YTD 2016, with organic growth of parts and services revenue of 4.1%. Net income was $291.7 million.
- Segment EBITDA margins were 12.4% for Q2 2017 and YTD 2017, down from 13.0% for Q2 2016 but flat compared to 12.7% for YTD 2016.
- The company reported revenue of $2.34 billion for Q1 2017, up 21.9% from Q1 2016, driven by organic growth, acquisitions, and higher scrap steel prices.
- Income from continuing operations was $140.8 million for Q1 2017 compared to $112.2 million for Q1 2016.
- Segment EBITDA margin was 12.4% for Q1 2017 compared to 12.3% for Q1 2016, as revenue growth offset increased operating expenses from acquisitions.
Barry Callebaut Group - Half-Year Results Fiscal Year 2017/18 - Media/Analyst...Barry Callebaut
Antoine de Saint-Affrique, CEO of the Barry Callebaut Group, said: “We had a very strong performance in the first six months of the current fiscal year, which was supported by all product groups and regions, as well as our key growth drivers. This resulted in the continued improvement of our profitability, driven by a favorable mix, operational leverage and a more supportive market.”
Bruker reported financial results for Q3 2018 and year-to-date Q3 2018. Q3 revenue increased 7.1% year-over-year to $466.6 million driven by 7% organic growth. Non-GAAP operating income grew 27% and margin expanded 280 basis points. Year-to-date revenue increased 8.6% to $1,342 million with organic growth of 4.7%. Non-GAAP EPS grew 28% in Q3 and 23% year-to-date as revenue growth and margin expansion drove higher profits. Bruker aims to continue revenue growth acceleration through initiatives like acquisitions and new facilities.
Oshkosh Corporation reported its financial results for the second quarter of fiscal year 2017. Net sales increased 6.2% to $1.618 billion compared to the same period last year, and adjusted earnings per share were $0.76, equal to the prior year. The defense segment performed well due to the JLTV program ramp up and international sales. The access equipment and commercial segments faced challenges with lower sales volumes impacting operating income. For fiscal year 2017, the company increased its adjusted EPS outlook to a range of $3.20 to $3.50.
- Cardinal Health reported Q4 FY2017 revenue of $32.966 billion, a 5% increase over the prior year. Operating earnings were $439 million, a 29% decrease.
- Revenue in the Pharmaceutical segment increased 5% to $29.552 billion driven by distribution customer and specialty solutions growth. Segment profit decreased 7% to $505 million due to generic pricing and IT investment.
- The Medical segment saw 6% revenue growth to $3.416 billion from new and existing customers. Segment profit rose 13% to $138 million from post-acute solutions and distribution growth.
The document recommends buying shares of Busan City Gas (BCG) based on the following points:
1. BCG has a monopoly on natural gas distribution in Busan, Korea, generating predictable cash flows. However, its stock price fell due to a one-time earnings decline and now offers upside.
2. BCG's intrinsic value exceeds its stock price, which fails to account for undervalued real estate assets.
3. The majority owner of BCG may fully acquire the company, unlocking its true value for shareholders.
This annual report provides information on China Mobile Limited for the 2008 fiscal year. It includes the chairman's statement which discusses the company maintaining growth in new customers, business, and voice usage. Financial highlights show increases in key financial figures such as revenue and profit for the year from 2005 to 2008. The business review discusses the company expanding its subscriber base and stimulating voice usage. The financial review analyzes expenses and their increases from the prior fiscal year.
A survey found that:
- 79% of respondents saw their sales reduce in 2020, with over 40% seeing a reduction of over 50% compared to 2019.
- 62% of respondents reduced their purchases due to Covid-19 across many locations and industries.
- 70% of respondents experienced delays with their orders.
- 70% of respondents were willing to accept delays of over 10 days from suppliers because of Covid-19.
- 86% of respondents were optimistic that 2021 will be better than 2020.
This document provides a summary of Ingersoll Rand's first quarter 2017 results. Some key points:
- Revenue increased 4% year-over-year on an organic basis to $3 billion. Adjusted EPS increased 14% to $0.57.
- Commercial and residential HVAC businesses saw strong revenue and bookings growth in the high-single digits. Industrial business bookings were up 9%.
- Adjusted operating margins improved in both the climate and industrial segments.
- Guidance for full-year 2017 revenue growth remains at 2-3% organic and adjusted EPS is increased to a range of $4.35 to $4.50.
- The document provides an earnings conference call summary for Q4 and Fiscal Year 2017.
- Key highlights include net sales growth of 12% in Q4 and 9% for FY 2017, and operating profit before special items growth of 2% in Q4 and 9% for FY 2017.
- Class A EPS before special items grew 51% in Q4 to $0.98 per share and grew 21% for FY 2017 to $2.95 per share.
- The document outlines Greif's December 2017 investor meetings, including forward-looking statements, regulation G definitions, and Greif's business segments.
- Greif has four business segments: Rigid Industrial Packaging & Services (RIPS), Paper Packaging & Services (PPS), Flexible Products & Services (FPS), and Land Management.
- Greif has a global footprint with operations in over 40 countries and focuses on customer service excellence through its Greif Business System (GBS).
In the first six months of 2017, NNIT saw revenue growth of 6.3% to DKK 1,404 million. Operating profit increased 6.3% to DKK 133 million and net profit grew 11.7% to DKK 103.4 million. Order backlog increased 5.4% to DKK 2,659 million. Revenue growth was driven by life sciences customers outside Novo Nordisk and new customers in the enterprise segment. Operating profit margin declined slightly due to lower margin projects from Novo Nordisk and onboarding new customers. The outlook for 2017 remains unchanged with organic revenue growth of 3-5% and an operating profit margin above 9%.
Bruker Corporation reported financial results for Q3 2017 and year-to-date Q3 2017. Revenue increased 10.6% in Q3 2017 and 8.3% year-to-date, driven by organic growth and acquisitions. Operating profit grew 10% in Q3 2017 and 13% year-to-date. However, earnings per share declined in both periods compared to the prior year due to a higher effective tax rate in 2017. The company continues to focus on revenue growth, margin expansion, and portfolio transformation through new product development and acquisitions.
First three months of 2017 Roadshow presentationNNiTInvestor
NNIT reported financial results for the first quarter of 2017. Revenue increased 4.3% to DKK 715 million, while operating profit rose 8% to DKK 73 million. Order backlog grew 7.9% organically to DKK 2,385 million. NNIT also announced the renewal of its global infrastructure agreement with Novo Nordisk and the acquisition of Dynamics AX consultancy SCALES.
Klöckner & Co SE - Q2 2017 Results - Press ConferenceKlöckner & Co SE
- Klöckner & Co reported sales of €1.64 billion for Q2 2017, up 8.1% year-over-year, while shipments were down 4.4% adjusted for business sales and discontinuations.
- EBITDA for Q2 was €63 million, within guidance of €60-70 million. EBITDA for the first half of 2017 was €140 million, up from €88 million in the prior year period.
- The company expects EBITDA of €35-45 million for Q3 2017 and an increase of over 10% in full year EBITDA compared to 2016.
Leonardo's 1Q 2017 results presentation summarizes the company's financial performance for the first quarter of 2017. Key highlights include:
- New orders were in line with or above expectations across sectors such as helicopters, electronics, and aeronautics.
- Revenues were softer than the previous quarter due to expected lower volumes, though profitability continued to improve across sectors driven by efficiency improvements.
- Guidance for full-year 2017 is confirmed, with expectations for revenues to remain around 2016 levels and further improvements in profitability.
- Bruker reported revenue growth of 2.5% year-over-year for Q1 2017 to $384.9 million, driven by acquisitions offsetting declines in organic and currency revenue.
- Non-GAAP gross margin expanded 90 basis points and non-GAAP operating margin grew 20 basis points compared to Q1 2016.
- EPS declined to $0.19 per share from $0.21 per share in Q1 2016 due to a higher effective tax rate in the current period.
- Net banking income was €139.4 million in 1Q 2018, driven by strong contributions from the NPL BU and double-digit growth in the Enterprises Segment.
- Net profit was €37.9 million with a cost of credit of 73 basis points.
- The balance sheet remains solid with shareholders' equity of €1.413 billion and a CET1 ratio of 15.49%.
- Snam reported an 8.1% increase in natural gas volumes transported in the first 9 months of 2017, with increases in both thermoelectric (+13.8%) and industrial (+7.6%) gas demand.
- Revenues increased 1.9% to €1,896 million due to higher gas volumes and a rise in the Regulated Asset Base (RAB). EBIT increased 3.3% to €1,063 million from efficiencies, a lower cost of debt, and higher income from associates.
- Net profit was solid at €755 million, up 18.2% compared to the same period in 2016, benefiting from significant cost of debt optimization and an increased contribution from
- E-commerce gross profit increased 15% to SEK 162m and Financial Services reached operating profitability before depreciations. Group operating income before depreciation improved SEK 26m.
- CDON Marketplace increased external merchant sales by 93% and Nelly substantially increased profits. Qliro Financial Services became a credit market company.
- However, Lekmer remained weak with declining sales in Sweden, partly offset by growth in Norway, Denmark and Finland.
Klöckner & Co SE - Q1 2017 Results - Press ConferenceKlöckner & Co SE
Klöckner & Co reported strong results for Q1 2017, with EBITDA more than quadrupling compared to Q1 2016. Sales increased 15.6% driven by higher prices. The gross profit margin increased due to rising steel prices and a focus on value-added products and services. The company's digitalization and One Europe restructuring strategies contributed to the improved results and remain a focus. Klöckner expects EBITDA to increase noticeably for FY 2017 compared to 2016.
4Q17/2017 Results Presentation - CPFL EnergiaCPFL RI
This document provides an overview of 4Q17/2017 results for an unnamed company. Some key highlights include:
- Net income increased 35.3% in 4Q17 and 39.9% for 2017. EBITDA also increased significantly.
- Sales increased in the company's concession area due to higher demand and acquisitions.
- Investments totaled R$694 million in 4Q17 and R$2.6 billion in 2017 to expand and maintain infrastructure.
- Generation performance was impacted by lower reservoir levels and wind generation below expectations.
Q2 2016 Earnings Presentation - Bruker CorporationInvestorBruker
- Bruker reported a 6% decline in Q2 revenue to $371.7M, driven primarily by delays in European academic funding and weaker industrial markets. With cost actions, non-GAAP gross profit margin expanded 250 bps to 47.6% and non-GAAP operating margin was flat at 10.8%.
- For H1 2016, revenue was essentially flat at $747.1M. Non-GAAP gross profit margin increased 110 bps to 47.2% and non-GAAP operating margin expanded 120 bps to 11.7%, resulting in 28% growth in non-GAAP EPS.
- Key priorities for 2016 include continuing margin expansion, strengthening business processes, and acceler
- Qlirogroup reported increased net sales of 2% and gross margin up 4.2 percentage points for Q4 2016.
- CDON Marketplace external merchant sales grew 75% in Q4. Nelly's operating income improved significantly by over SEK 30m.
- Qliro Financial Services saw a 70% increase in revenue and a positive profit before tax of SEK 11.2m for Q4 2016.
Solvay 9 months 2018 results - PresentationSolvay Group
Solvay published on November 8, 2018 its first nine months 2018 results. Earnings toolkit and press release are available here: https://www.solvay.com/en/event/nine-months-2018-earnings
We've delivered a strong financial performance in 2021, making significant progress on our new strategic plan.
#SGS #SGSGroup #WeAreSGS #FinancialResults
Leonardo presented its 3Q/9M 2017 financial results. Helicopter division results were weaker than expected due to ongoing market and execution challenges. While Aeronautics and Defense Electronics results were broadly in line with expectations, the overall 2017 guidance was made tougher reflecting issues in Helicopters. Actions have been taken to address Helicopter issues including management changes and optimizing production processes. Overall, the company remains confident in its medium-term growth opportunities across its three key pillars of Helicopters, Defense Electronics, and Aeronautics.
We are very satisfied with the strong nine month and third quarter results. They show that we are delivering on the promises of our Ambition 2018 strategic plan. The combined ratio, margins in guaranteed life, return on equity and solvency all exceed our targets.
Similar to Q3 2017 financial release presentation (20)
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4study presented by a Big 4
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdfSOFTTECHHUB
The world of blockchain and decentralized technologies is about to witness a groundbreaking event. ZKsync, the pioneering Ethereum Layer 2 network, has announced the highly anticipated airdrop of its native token, ZK. This move marks a significant milestone in the protocol's journey, empowering the community to take the reins and shape the future of this revolutionary ecosystem.
The E-Way Bill revolutionizes logistics by digitizing the documentation of goods transport, ensuring transparency, tax compliance, and streamlined processes. This mandatory, electronic system reduces delays, enhances accountability, and combats tax evasion, benefiting businesses and authorities alike. Embrace the E-Way Bill for efficient, reliable transportation operations.
Cleades Robinson, a respected leader in Philadelphia's police force, is known for his diplomatic and tactful approach, fostering a strong community rapport.
Methanex is the world's largest producer and supplier of methanol. We create value through our leadership in the global production, marketing and delivery of methanol to customers. View our latest Investor Presentation for more details.
UnityNet World Environment Day Abraham Project 2024 Press ReleaseLHelferty
June 12, 2024 UnityNet International (#UNI) World Environment Day Abraham Project 2024 Press Release from Markham / Mississauga, Ontario in the, Greater Tkaronto Bioregion, Canada in the North American Great Lakes Watersheds of North America (Turtle Island).
2. The NNIT Presenting Team
2
Jesper Wagener
Head of Investor Relations
Carsten Krogsgaard
Thomsen
Chief Financial Officer
Per Ove Kogut
Chief Executive Officer
4. Forward looking statements
This presentation contains forward-looking statements. Words such as ‘believe’, ‘expect’,
‘may’, ‘will’, ‘plan’, ‘strategy’, ‘prospect’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’,
‘intend’, ‘outlook’, ‘guidance’, ‘target’ and other words and terms of similar meaning in
connection with any discussion of future operating or financial performance identify
forward-looking statements. Statements regarding the future are subject to risks and
uncertainties that may result in considerable deviations from the outlook set forth.
Furthermore, some of these expectations are based on assumptions regarding future
events which may prove incorrect.
4
5. First nine months of 2017 at a glance
5
Revenue
DKK 2,080m
Operating profit
DKK 164m
Operating profit margin
7.9%
Net profit
DKK 130m
Order backlog
DKK 2,750m
Free cash flow
DKK -78m
-16.6%+4.2% -2.0pp
+3.3%-9.3% DKK -196m
+2.1% organic* -21.1% organic* -2.2pp organic*
*Organic is growth net of acquisitions and F/X using 9M 2016 average exchange rates
+2.2% acquisition
+0.0% F/X
+2.0% acquisition
+2.5% F/X
+0.0pp acquisition
+0.2pp F/X
6. Q3 2017 at a glance
6
Revenue
DKK 676m
Operating profit
DKK 31m
Operating profit margin
4.5%
Net profit
DKK 27m
Order backlog addition
DKK 91m
Free cash flow
DKK -55m
-56.2%+0.2% -5.8pp
-35.4%-47.6% DKK -75m
-4.2% organic* -65.4% organic* +3.7pp organic*
*Organic is growth net of acquisitions and F/X using Q3 2016 average exchange rates
+4.6% acquisition
-0.3% F/X
+4.7% acquisition
+4.5% F/X
+0.3pp acquisition
+0.5pp F/X
7. Backlog development
Backlog for 2017 is DKK 2,750m, which is an increase
of 3.3% compared to same time in 2016.
• SCALES accounts for 1.9pp of the backlog growth
• The one-off settlement decreased the backlog with
around 1.2pp.
The underlying organic growth is thus 2.6%.
The organic backlog growth is driven by:
• New customers in the enterprise and life sciences
customer groups
• Expansion of contracts with existing customers
in the enterprise and life sciences customer group.
• Partly countered by a lower backlog with the Novo
Nordisk Group
The backlog for 2018 and 2019 decreased 6.2% y-o-y
to DKK 2,767m:
• Novo Nordisk backlog increased by 2.5% mainly due
to renewal of the global infrastructure agreement
• Several large outsourcing contracts expire in 2018
and 2019 and are not yet renegotiated or retendered
• All renewals or replacements of these contracts will
increase the backlog
7
8. Amount Length
(DKK million) (years)
Mid-size double-digit 5
Extension of SAP outsourcing contract Enterprise Existing customer Mid-size double-digit 6
Minor double-digit 2
Minor double-digit 3
New SAP Advanced Track and Trace for Pharmaceuticals
implementation
Life sciences Existing customer
Mid-size double-digit 5
GxP application outsourcing contract Life sciences Existing customer Mid-size double-digit 5
Contract Segment Client
Infrastructure outsourcing agreement Novo Nordisk Novo Holdings
Compliance-as-a-Service contract Life sciences Existing customer
Infrastructure outsourcing agreement
(Mentioned in Q2 2017 report)
Life sciences New customer
Q3
2017
Major wins
8
9. Other business
9
Settlement on an arbitration
(company announcement 8/2017)
• Arbitration case from 2014
• Settlement results in a one-time revenue reversal of DKK 33 million with
similar impact on operating profit
DSB
• Tender according to public regulation
• The negative impact is a minor double-digit DKK million amount reduction in
2018 and a further mid-size double-digit DKK million reduction in 2019
New head of Solutions
• New head of IT Solution Services: Claus Middelboe Andersen
• Currently CIO at SKAT (Danish Tax Authorities).
10. Revenue 2,112.7 2,079.7 1,995.7 4.2% -1.7pp 2.2pp
Cost of goods sold 1,731.0 1,731.0 1,616.6 7.1% 0pp 2.4pp
Gross profit 381.6 348.6 379.1 -8.0% -8.7pp 1pp
Gross profit margin 18.1% 16.8% 19.0% -2.2pp -1.2pp -0.2pp
Sales and marketing costs 99.6 99.6 98.1 1.6% 0pp 0pp
Administrative expenses 85.4 85.4 84.9 0.6% 0pp 0pp
Operating profit 196.6 163.6 196.1 -16.6% -16.8pp 2pp
Operating profit margin 9.3% 7.9% 9.8% -2pp -1.4pp 0pp
Net financials 0.8 0.8 -10.5 -107.8% n.a. n.a.
Profit before tax 197.4 164.4 185.6 -11.4% -17.8pp 2.1pp
Tax 41.6 34.3 42.1 -18.5% -17.2pp 2.8pp
Effective tax rate 21.1% 20.9% 22.7% -1.8pp -0.2pp 0.2pp
Net profit 155.8 130.1 143.5 -9.3% -17.9pp 1.9pp
Change
(reported)
Settlement
impact
SCALES
impact
DKK million
9M 2017
before
settlement
9M 2017
(reported)
9M 2016
Financial statement 9M 2017
10
Revenue growth of 4.2% being negatively impacted by the
one-off revenue reversal of DKK 33m corresponding to 1.7pp.
Excluding the one-off revenue reversal, growth was 5.9%
Positively impact from SCALES of 2.2pp giving an underlying
organic growth of 3.7% excl. settlement and M&A.
Cost of goods sold increased by 7.1% and exceeds revenue
growth due to lower activity level for higher margin projects
from the Novo Nordisk Group, price reductions in certain
outsourcing contracts and onboarding of new customers
Sales and marketing costs increased by 1.6% mainly
due strengthening of the sales force especially within
international life sciences.
Administrative expenses increased by 0.6% mainly due
cost cautiousness in general.
Effective tax rate declined 1.8pp primarily due to non-
taxable income regarding unrealized gain from Novo
Nordisk shares and due to non-taxable income
regarding energy savings
11. Revenue 708.6 675.6 674.5 0.2% -4.9pp 4.6pp
Cost of goods sold 582.3 582.3 543.8 7.1% 0pp 5.2pp
Gross profit 126.3 93.3 130.7 -28.6% -25.3pp 2.5pp
Gross profit margin 17.8% 13.8% 19.4% -5.6pp -4pp -0.2pp
Sales and marketing costs 33.9 33.9 31.6 7.4% 0pp 0pp
Administrative expenses 28.9 28.9 29.4 -1.6% 0pp 0pp
Operating profit 63.6 30.6 69.7 -56.2% -47.3pp 4.7pp
Operating profit margin 9.0% 4.5% 10.3% -5.8pp -4.4pp 0.3pp
Net financials 3.6 3.6 -2.7 -233.4% n.a. n.a.
Profit before tax 67.2 34.2 67.0 -49.0% -49.2pp 4.8pp
Tax 14.7 7.5 16.1 -53.5% -45.1pp 6.0pp
Effective tax rate 22.0% 21.9% 24.0% -2.1pp 0pp 0.8pp
Net profit 52.4 26.7 50.9 -47.6% -50.5pp 4.5pp
Q3 2017
before
settlementDKK million
Q3 2017
(reported)
Change
(reported)
Q3 2016
Settlement
impact
SCALES
impact
Financial statement Q3 2017
11
Revenue growth of 0.2% being negatively impacted by the
one-off revenue reversal of DKK 33m corresponding to 4.9pp.
Excluding the one-off revenue reversal, growth was 5.1%
Positively impact from SCALES of 4.6pp giving an underlying
organic growth of 0.4% excl. settlement and M&A.
Cost of goods sold increased by 7.1% and exceeds revenue
growth due to lower activity level for higher margin projects
from the Novo Nordisk Group, price reductions in certain
outsourcing contracts and onboarding of new customers
Sales and marketing costs increased by 7.4% mainly
due strengthening of the sales force especially within
international life sciences.
Administrative expenses decreased by 1.6% due to
timing of expenses and cost cautiousness in general.
Effective tax rate declined 2.1pp primarily due non-
taxable income regarding unrealized gain from Novo
Nordisk shares
12. Life Sciences 386.5 386.8 -0.1% 1,165.5 1,165.9 0.0%
Hereof Novo Nordisk Group 291.3 298.3 -2.3% 882.2 909.7 -3.0%
Hereof other Life Sciences 95.2 88.6 7.5% 283.3 256.1 10.6%
Enterprise 182.0 144.7 25.8% 496.2 375.2 32.3%
Public 54.7 90.4 -39.5% 231.3 281.8 -17.9%
Finance 52.5 52.6 -0.2% 186.7 172.9 8.0%
Total 675.6 674.5 0.2% 2,079.7 1,995.7 4.2%
DKKm
9M 2017 9M 2016 ChangeChangeQ3 2017 Q3 2016
Novo Nordisk revenue decreased by 3.0%
(Q3: -2.3%) mainly related to a reduction in the service
level agreements in IT Operation Services and
significantly lower project activity within IT Solution
Services.
Life sciences revenue outside Novo Nordisk grew by
10.6% (Q3: 7.5%) reflecting an increased activity level
especially from a number of international customers.
Enterprise revenue grew by 32.3% (Q3: 25.8%) driven
by increased revenue from new customers secured in
2016 such as PANDORA and Widex as well as SCALES
customers
Public revenue decreased by 17.9% (Q3: -39.5%). The
decline in 9M 2017 and in Q3 in particular was impacted
by the one-off revenue reversal of DKK 33m. Excluding
the revenue reversal, the declined was 6.2% (Q3: -
2.9%) negatively impacted by another settlement with
a customer within IT Operation Services in Q1 2017 and
price reductions in certain outsourcing contracts.
Finance revenue increased 8.0% (Q3: -0.2%) primarily
due to contract wins with new customers such as
E-nettet and Danske Bank, partly countered by a
customer within IT Operation Services, which expired
June 2017 and was not extended
Segment development
12
13. DKKm Q3 2017 Q3 2016 Change 9M 2017 9M 2016 Change
Revenue
Novo Nordisk Group 203.5 203.0 0.2% 610.4 615.5 -0.8%
Non-Novo Nordisk Group 247.6 244.1 1.5% 743.4 692.6 7.3%
Total 451.1 447.1 0.9% 1,353.7 1,308.0 3.5%
Costs 400.9 393.9 1.8% 1,209.9 1,168.9 3.5%
Operating profit 50.3 53.1 -5.4% 143.9 139.1 3.4%
Operating profit margin 11.1% 11.9% -0.7pp 10.6% 10.6% 0pp
IT Operations
Revenue growth of 3.5% (Q3: 0.9%):
• Driven by new large customers such as
PANDORA, Danske Bank and the life sciences
customer group, partly countered by Novo
Nordisk and the finance customer group
• The decline from Novo Nordisk relates to the
reduction in the service level agreements in IT
Operation Services and lower project activity
Operating profit margin was unchanged at 10.6%
(Q3: decreased 0.7pp to 11.1%):
• The decrease in Q3 was due to by low project
activity with good margins which has partly been
replaced by hardware sales with low margins
13
14. DKKm Q3 2017 Q3 2016 Change
Settle-
ment
Scales
Revenue
Novo Nordisk Group 87.8 95.3 -7.8% 0pp 0pp
Non-Novo Nordisk Group 136.7 132.1 3.5% -25.0pp 23.7pp
Total 224.5 227.4 -1.2% -14.5pp 13.8pp
Costs 244.2 210.8 15.9% 0pp 13.3pp
Operating profit -19.7 16.6 n.a n.a. 19.7pp
Operating profit margin -8.8% 7.3% -16.1pp -16.3pp 3.1pp
14
IT Solutions
DKKm 9M 2017 9M 2016 Change
Settle-
ment
Scales
Revenue
Novo Nordisk Group 271.8 294.3 -7.6% 0pp 0pp
Non-Novo Nordisk Group 454.1 393.4 15.4% -8.4pp 10.9pp
Total 725.9 687.7 5.6% -4.8pp 6.2pp
Costs 706.2 630.7 12.0% 0pp 6.2pp
Operating profit 19.7 57.0 -65.4% -57.9pp 6.8pp
Operating profit margin 2.7% 8.3% -5.6pp -4.5pp 0.4pp
Operating profit margin decreased to 2.7%
(Q3: -8.8%) impacted by the one-off revenue reversal.
Excluding the revenue reversal Operating profit margin
was 7.2% (Q3: 7.5%)
• The underlying profit was negatively impacted by
reduction in higher margin project activities from
the Novo Nordisk Group and price and scope
reductions on certain outsourcing contracts
Revenue increased 5.6% (Q3: -1.2%) negatively
impacted by the one-off revenue reversal of DKK
33m. Excluding the revenue reversal growth was
10.4% (Q3: 13,3%)
Revenue from Novo Nordisk decreased 7.6% (Q3:
-7.8%) due to decline in project activities.
Customers outside the Novo Nordisk Group increased
23.8% (Q3: 28.5%) if excluding the revenue reversal.
15. Hedging period
(months)
EUR DKK 34 million -
CNY DKK -18 million 14
CZK DKK -10 million 14
PHP DKK -4 million -
CHF DKK -1 million -
USD DKK -1 million -
*The above sensitivities address hypothetical situations and are provided for illustrative
purposes only. The sensitivities assume our business develops consistent with our current
2017 business plan.
Hedging gains and losses do not impact operating profit as they are recognized under net
financials.
Estimated annual impact on NNIT’s operating profit of a 10%
increase in the outlined currencies against DKK*
Currency development and hedging
15
Major currencies except CZK have
all been depreciating lately versus
the DKK.
CZK appreciated against DKK.
We see currency tailwind from the
CNY and PHP compared to 2016,
while we have currency headwind
from CZK compared to 2016.
9M 2017 our operating profit
margin tailwind was 0.2pp
compared to 2016 exchange rates
primarily due to the CNY.
16. Net Financial impact from Novo Nordisk share price
DKKm
Market
value Obligation Net
Full year 2017 (if the share price increase by 10%) 1.3 1.3 0.0
Full year 2017 (if the share price decrease by 10%) -1.3 -1.3 0.0
Total Currency hedges
DKKm 9M 2017 9M 2016 Change
Currency hedge gains in P&L 1.4 -5.2 6.7
Currency hedge gains on Equity 0.1 0.0 0.1
Total currency hedge gains 1.6 -5.2 6.8
Net financials
DKKm 9M 2017 9M 2016 Change
Net gains on Novo Nordisk shares* 0.2 -3.7 3.9
Dividends received from Novo Nordisk shares 0.3 0.7 -0.4
Total Novo Nordisk share related items 0.5 -3.0 3.5
Currency hedge gains 1.4 -5.2 6.7
Currency losses 1.0 -0.1 1.1
Total currency related items 2.5 -5.3 7.8
Interests and bank charges** -2.2 -2.2 0.0
Total interests and bank charges -2.2 -2.2 0.0
Net financials 0.8 -10.5 11.3
* Market value of Novo Nordisk shares less adjustment of obligation realted to long-term incentive programs from previous years.
** Includes fees to banks in relation to being a public listed company
Net Financials
Net financials for 9M 2017 were DKK
0.8m, which was DKK 11.3m better
than 9M 2016.
This was due to:
• Improvement in result from
Novo Nordisk shares held for
management long-term incentive
program from before 2015 (DKK
0.2m) compared to 9M 2016 (DKK
-3.7m)
• Gains on currency hedges (DKK
2.5m) compared to 9M 2016 (DKK
-5.3m) due to a depreciations in
exposed currencies
16
17. Employee development
Number of employees increased by 7.5% to
2,999 FTE end of September 2017. This is
primarily driven by the acquisition of SCALES,
which increased Western manning by 119 FTE.
Excluding SCALES, the number of employees
increased 3.1%. The increase was outside
Denmark and in-line with the long-term
offshoring strategy.
Number of employees in Western countries
increased 91 FTE (5.5%). Excluding SCALES, the
number of employees decreased 28 FTE (-1.7%).
Growth in China, the Czech Republic and the
Philippines was 117 FTE (10.2%)
Share of employees in low cost countries was
42.0% end of September 2017. Excluding
SCALES, the share was 43.7% compared to
40.9% in September 2016.
17
*Western countries: Denmark, Germany, Norway, Switzerland, United
Kingdom, United States
18. Equity and liabilities
DKKm 9M 2017 9M 2016
Share capital 250.0 250.0
Treasury shares -6.6 -7.5
Retained earnings 659.4 509.2
Other reserves 4.8 6.5
Total equity 907.6 758.1
Deferred tax 0.3 0.0
Employee benefit obligation 18.7 29.7
Provisions 67.9 10.0
Total non-current liabilities 86.9 39.7
Prepayments received 146.7 64.0
Trade payables 74.8 57.2
Employee cost payable 250.8 237.2
Bank Debt 67.7 0.0
Tax payables 20.0 2.9
Other current liabilities 135.7 110.2
Derivative financial instruments 3.1 1.4
Employee benefit obligation 14.5 6.5
Provisions 0.0 8.1
Total current liabilities 713.3 487.6
Total equity and liabilities 1,707.9 1,285.4
Assets
DKKm 9M 2017 9M 2016
Intangible assets 207.2 21.7
Tangible assets 530.2 409.6
Deferred tax 53.0 28.4
Other financial assets 32.5 28.7
Total non-current assets 822.9 488.4
Inventories 1.7 2.5
Trade receivables 496.5 432.5
Work in progress 128.1 130.8
Other receivables and pre-payments 181.3 101.3
Tax receivables 0.0 3.5
Shares 12.9 21.1
Derivative financial instruments 3.0 1.4
Cash and cash equivalents 61.4 103.8
Total Current assets 885.0 797.0
Total assets 1,707.9 1,285.4
Balance sheet
18
19. Cash flow
DKKm 9M 2017 9M 2016 Change
Net profit for the period 130.1 143.5 -13.4
Reversal of non-cash items 151.0 176.1 -25.1
Net interest and taxes paid -51.6 -38.8 -12.8
Changes in working capital 20.1 -46.6 66.7
Cash flow from operating activities 249.6 234.1 15.5
Capitalization of intangible assets -3.0 0.0 -3.0
Purchase of tangible assets -227.2 -112.3 -114.9
Change in trade payables related to investments 3.1 -6.1 9.2
Sale of tangible assets 0.0 2.2 -2.2
Dividends received 0.3 0.7 -0.4
Payment of deposits -2.9 -0.4 -2.6
Acquisition of subsidiary -98.0 0.0 -98.0
Cash flow from investing activities -327.7 -115.8 -211.9
Dividends paid -102.0 -145.5 43.5
Cash flow from financing activities -102.0 -145.5 43.5
Net cash flow -180.1 -27.2 -152.9
Free cash flow -78.1 118.3 -196.4
Cash flows
Cash flow from operating activities was
DKK 249.6m, which was DKK 15.5m
higher due to positive development in
working capital.
Cash flow from investing activities was
DKK -327.7m compared to DKK -115.8m
in 9M 2016 due to acquisition of SCALES
and investments primarily related to a
new datacenter.
Cash flow from financing activities was
DKK -102m compared to DKK -145.5m in
9M 2016 due to interim dividend payouts
mid 2017.
Free cash flow was DKK -78.1m, which is
DKK 196.4m below 9M 2016 due to
above-mentioned investment in SCALES
and a new data center.
19
20. Constant currencies: Around 10%
Reported currencies: 0.3pp higher
Share of revenue:
Share of revenue excl. SCALES:
15-17%
12-14%
Relating to new data center: 7pp or around
DKK 200m
Total data center investment: DKK 250m
Outlook
Revenue
growth
Capex
Operating
margin
2017
20
Previous guidance (6 months 2017)
Constant currencies: 4-6%
Constant currencies (organic): 1-3%
Reported currencies: 0.2pp lower
Constant currencies: Around 9%
Reported currencies: 0.3pp higher
Share of revenue:
Share of revenue excl. SCALES:
15-17%
12-14%
Relating to new data center: 7pp or around
DKK 200m
Total data center investment: DKK 250m
Constant currencies: 4-8%
Constant currencies (organic): 1-5%
Reported currencies: 0.2 pp lower
21. Closing remarks
• Continued growth in non-Novo Nordisk revenue
• Uncertainty in revenue from Novo Nordisk persists
• While uncertainty from Novo Nordisk may impact 2018, NNIT continues to
believe that the long-term target of growing revenue by at least 5% is
still achievable.
• One-time impact in Q3 on a settlement of an old arbitration
• Revenue guidance is narrowed to 4-6% revenue, while operating profit
margin is now expected to be around 9% with an investment level of
15-17% of revenue
• Both revenue growth and operating profit margin are negatively impacted
by a one-time revenue reversal due to settlement of an arbitration
21
22. Investor contact information
22
Upcoming events
December 12, 2017: Danske Bank Copenhagen Winter Seminar
January 10, 2018: SEB Nordic Seminar
January 25, 2018: Financial statement for the full year 2017
Investor contact
NNIT A/S
Østmarken 3A
2860 Søborg
Denmark
Jesper Wagener
+45 3075 5392
jvwa@nnit.com